0.5401

0.95% 0.0051

After Hours: .52 -0.0201 -3.72%

Spruce Biosciences Inc (SPRB)

Overview News Price History Financials Discussions Forecast

Spruce Biosciences Inc stock is traded at $0.5401, with a volume of 75,561. It is up +0.95% in the last 24 hours and up +18.47% over the past month. Spruce Biosciences Inc is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with unmet medical needs. The company is initially developing its wholly-owned product candidate, tildacerfont, as the potential first non-steroidal therapy to offer markedly improved disease control and reduce steroid burden for patients suffering from classic congenital adrenal hyperplasia (CAH).

Previous Close:

$0.535

Open:

$0.5416

24h Volume:

75,561

Relative Volume:

0.18

Market Cap:

$22.43M

Revenue:

$9.57M

Net Income/Loss:

$-43.11M

P/E Ratio:

-0.3234

EPS:

-1.67

Net Cash Flow:

$-49.54M

1W Performance:

-8.44%

1M Performance:

+18.47%

6M Performance:

-27.44%

1Y Performance:

-50.68%

1-Day Range:

$0.5228

$0.5491

1-Week Range:

$0.4963

$0.5898

52-Week Range:

$0.4112

$5.95

Spruce Biosciences Inc Stock (SPRB) Company Profile

Name

Spruce Biosciences Inc

Sector

Healthcare (1182)

Industry

Biotechnology (671)

Phone

(415) 655-4168

Address

611 GATEWAY BOULEVARD, SUITE 740, SOUTH SAN FRANCISCO

Employee

Twitter

Next Earnings Date

2024-11-11

Latest SEC Filings

SPRB's Discussions on Twitter

Spruce Biosciences Inc Stock (SPRB) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-17-21	Initiated	Oppenheimer	Outperform
Dec-10-21	Initiated	The Benchmark Company	Speculative Buy
Nov-16-21	Downgrade	SVB Leerink	Outperform → Mkt Perform
Jul-19-21	Initiated	H.C. Wainwright	Buy
Apr-26-21	Resumed	Credit Suisse	Outperform
Nov-03-20	Initiated	Cowen	Outperform
Nov-03-20	Initiated	Credit Suisse	Outperform
Nov-03-20	Initiated	RBC Capital Mkts	Outperform
Nov-03-20	Initiated	SVB Leerink	Outperform

View All

Spruce Biosciences Inc Stock (SPRB) Latest News

Nov 01, 2024

Layoff Tracker: Compass Pathways to Lay Off 30% of Employees - BioSpace

Nov 01, 2024

Oct 28, 2024

Spruce Biosciences faces Nasdaq delisting notice By Investing.com - Investing.com South Africa

Oct 28, 2024

Spruce Biosciences faces Nasdaq delisting notice - Investing.com

Oct 28, 2024

Spruce Biosciences to Participate in the Guggenheim Securities Healthcare Innovation Conference - StockTitan

Oct 28, 2024

Oct 22, 2024

Global Adrenogenital Syndrome Treatment Market to Reach USD 22.08 Billion in 2033, Driven by New The - PharmiWeb.com

Oct 22, 2024

Congenital Adrenal Hyperplasia Clinical Trials 2024: FDA Approvals, Companies, Medication, Treatment Market, Therapies, ROA and MOA by DelveInsight | Becton, Dickinson and Company, Cook Medical, MORE - Barchart

Oct 22, 2024

Oct 16, 2024

Floyd Mayweather Jr buying $402M Black Spruce portfolio - Yahoo Finance

Oct 16, 2024

Oct 15, 2024

Congenital Adrenal Hyperplasia (CAH) Therapeutic Market 2024 - openPR

Oct 15, 2024

Oct 12, 2024

Ambev S.A. (NYSE:ABEV) Given Average Rating of “Hold” by Brokerages - Defense World

Oct 12, 2024

Oct 10, 2024

Daily Progress: Spruce Biosciences Inc (SPRB) Drop -5.56, Closing at 0.43 - The Dwinnex

Oct 10, 2024

The Significance of Moving Averages in Spruce Biosciences Inc Inc. (SPRB) Price Performance - The InvestChronicle

Oct 10, 2024

Oct 03, 2024

A closer look at Spruce Biosciences Inc (SPRB)’s stock price trends - US Post News

Oct 03, 2024

Oct 02, 2024

North Carolina town that produces quartz needed for tech products is devastated by Helene - Yahoo Finance

Oct 02, 2024

Sep 30, 2024

Spruce Biosciences' SWOT analysis: tildacerfont trials key for CAH stock - Investing.com

Sep 30, 2024

Spruce Biosciences' SWOT analysis: tildacerfont trials key for CAH stock By Investing.com - Investing.com UK

Sep 30, 2024

Sep 24, 2024

Recent Insider Activity Suggests Potential Gains for Spruce Biosciences Inc (SPRB) - Knox Daily

Sep 24, 2024

Sep 20, 2024